Vorinostat effect in myeloid differentiation of CD33+ cells from AML patients.

Peripheral blood CD33+ cells from AML patients were cultured ex-vivo in the presence of 1 µM vorinostat or vehicle (control) and myeloid differentiation analyzed by flow cytometry with CD11b-PE plus CD13-APC or CD11b-PE plus CD13-APC and CD14-FITC antibodies. Cellular apoptosis was assessed by flow cytometry of annexin-V-FITC/7-AAD co-stained cells and viability by the MTT method. Results are percentage of cells per population subset. nd, not determined.